American depositary receipts of AstraZeneca were falling Monday after the drugmaker reported disappointing results from a Phase 3 trial of a lung- cancer drug.
July 3, 2023 - 15:10
By Pharos Investment Advisors Comments are Off
American depositary receipts of AstraZeneca were falling Monday after the drugmaker reported disappointing results from a Phase 3 trial of a lung- cancer drug.
June 9, 2023 - 18:00
By Pharos Investment Advisors Comments are Off
AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014
Copyright 2023©. All Rights Reserved